trial

Veeda Lifesciences announces partnership with Mango Sciences to bring AI innovation in clinical trials services

AHMEDABAD, India, July 8, 2025 /PRNewswire/ -- Veeda Lifesciences, a global contract research organization (CRO), has announced an investment in…

2 months ago

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025

SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing…

2 months ago

Green Crypto Revolution: Ripplecoin Mining Unveils Global AI-Powered Sustainable Cloud Mining with Free Trial

The new platform eliminates the participation barrier, integrates AI intelligence and green energy, and makes remote mining a passive income…

2 months ago

AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer

PRESS RELEASE MASITINIB RECEIVES FDA AND EMA AUTHORIZATION FOR CONFIRMATORY PHASE 3 TRIAL IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER, WITH BIOMARKER-DRIVEN…

2 months ago

Novotech Earns Frost & Sullivan’s 2025 Global Company of the Year Recognition for Excellence in Biotech Clinical Research Services

Recognized for its biotech-first focus, innovation in clinical trial delivery, and best-in-class client experience, Novotech sets the global standard in…

2 months ago

Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy

July 02, 2025 03:00 ET  | Source: Belite Bio, Inc -  500 subjects enrolled across the United States, the United…

2 months ago

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine

Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction in the highest range of…

3 months ago

Novo Nordisk: Higher dose of Wegovy provided average weight loss of 21% in people with obesity with a third achieving 25% or more according to data presented at ADA

Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25%…

3 months ago

Novo Nordisks subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025

Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people with overweight or obesity was…

3 months ago